Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Respir Res ; 23(1): 340, 2022 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-36496404

RESUMO

BACKGROUND: Premature infants, subjected to supplemental oxygen and mechanical ventilation, may develop bronchopulmonary dysplasia, a chronic lung disease characterized by alveolar dysplasia and impaired vascularization. We and others have shown that hyperoxia causes senescence in cultured lung epithelial cells and fibroblasts. Although miR-34a modulates senescence, it is unclear whether it contributes to hyperoxia-induced senescence. We hypothesized that hyperoxia increases miR-34a levels, leading to cellular senescence. METHODS: We exposed mouse lung epithelial (MLE-12) cells and primary human small airway epithelial cells to hyperoxia (95% O2/5% CO2) or air (21% O2/5% CO2) for 24 h. Newborn mice (< 12 h old) were exposed to hyperoxia (> 95% O2) for 3 days and allowed to recover in room air until postnatal day 7. Lung samples from premature human infants requiring mechanical ventilation and control subjects who were not mechanically ventilated were employed. RESULTS: Hyperoxia caused senescence as indicated by loss of nuclear lamin B1, increased p21 gene expression, and senescence-associated secretory phenotype factors. Expression of miR-34a-5p was increased in epithelial cells and newborn mice exposed to hyperoxia, and in premature infants requiring mechanical ventilation. Transfection with a miR-34a-5p inhibitor reduced hyperoxia-induced senescence in MLE-12 cells. Additionally, hyperoxia increased protein levels of the oncogene and tumor-suppressor Krüppel-like factor 4 (KLF4), which were inhibited by a miR-34a-5p inhibitor. Furthermore, KLF4 knockdown by siRNA transfection reduced hyperoxia-induced senescence. CONCLUSION: Hyperoxia increases miR-34a-5p, leading to senescence in lung epithelial cells. This is dictated in part by upregulation of KLF4 signaling. Therefore, inhibiting hyperoxia-induced senescence via miR-34a-5p or KLF4 suppression may provide a novel therapeutic strategy to mitigate the detrimental consequences of hyperoxia in the neonatal lung.


Assuntos
Displasia Broncopulmonar , Hiperóxia , Fator 4 Semelhante a Kruppel , MicroRNAs , Animais , Humanos , Camundongos , Animais Recém-Nascidos , Displasia Broncopulmonar/genética , Displasia Broncopulmonar/tratamento farmacológico , Dióxido de Carbono , Senescência Celular , Células Epiteliais/metabolismo , Hiperóxia/genética , Hiperóxia/metabolismo , Fator 4 Semelhante a Kruppel/genética , Fator 4 Semelhante a Kruppel/metabolismo , Pulmão/metabolismo , MicroRNAs/metabolismo
2.
Metabolites ; 10(9)2020 Aug 21.
Artigo em Inglês | MEDLINE | ID: mdl-32825609

RESUMO

Treatments with supplemental oxygen in premature infants can impair lung development, leading to bronchopulmonary dysplasia (BPD). Although a stage-specific alteration of lung lipidome occurs during postnatal lung development, whether neonatal hyperoxia, a known mediator of BPD in rodent models, changes lipid profiles in mouse lungs is still to be elucidated. To answer this question, newborn mice were exposed to hyperoxia for 3 days and allowed to recover in normoxia until postnatal day (pnd) 7 and pnd14, time-points spanning the peak stage of alveologenesis. A total of 2263 lung lipid species were detected by liquid chromatography-mass spectrometry, covering 5 lipid categories and 18 lipid subclasses. The most commonly identified lipid species were glycerophospholipids, followed by sphingolipids and glycerolipids. In normoxic conditions, certain glycerophospholipid and glycerolipid species augmented at pnd14 compared to pnd7. At pnd7, hyperoxia generally increased glycerophospholipid, sphingolipid, and glycerolipid species. Hyperoxia increased NADPH, acetyl CoA, and citrate acid but reduced carnitine and acyl carnitine. Hyperoxia increased oxidized glutathione but reduced catalase. These changes were not apparent at pnd14. Hyperoxia reduced docosahexaenoic acid and arachidonic acid at pnd14 but not at pnd7. Altogether, the lung lipidome changes throughout alveolarization. Neonatal hyperoxia alters the lung lipidome, which may contribute to alveolar simplification and dysregulated vascular development.

4.
Curr Opin Pediatr ; 17(2): 167-9, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15800405

RESUMO

PURPOSE OF REVIEW: To evaluate the safety and efficacy of metalloporphyrins for the treatment of neonatal hyperbilirubinemia. RECENT FINDING: Since the 1980s and 1990s, there have been no publications on trials to determine the efficacy of metalloporphyrins in the treatment of neonatal jaundice. In the past year, a single case report was presented on the compassionate use of tin mesoporphyrin in a very low birth weight infant with intrauterine growth retardation who did not respond to phototherapy. Subcutaneous administration of a single dose of tin mesoporphyrin at 46 hours of life was associated with a greater than 25% reduction in serum bilirubin. This further supports existing evidence that tin mesoporphyrin is efficacious in lowering bilirubin production. In the laboratory, most metalloporphyrins were shown to induce heme oxygenase, and in addition, metalloporphyrins modulate cardiac cell function in vitro. These observations suggest that the therapeutic benefits may be obviated if such considerations hold true in humans. SUMMARY: Recent case reports and previous evidence from larger clinical trials conducted in Greece and Argentina in the 1980s and 1990s demonstrate that tin mesoporphyrin is useful in the treatment of neonatal jaundice. Its long-term safety is not well understood but will be important to determine, before its widespread or prophylactic use in neonates with hyperbilirubinemia can be recommended.


Assuntos
Icterícia Neonatal/tratamento farmacológico , Metaloporfirinas/uso terapêutico , Bilirrubina/sangue , Bilirrubina/metabolismo , Humanos , Recém-Nascido , Metaloporfirinas/efeitos adversos , Metaloporfirinas/química , Estrutura Molecular , Resultado do Tratamento
5.
Liver Int ; 23(4): 232-42, 2003 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12895262

RESUMO

BACKGROUND/AIMS: Oxidative stress is presumed to play an important role in hepatic fibrogenesis. Diets high in polyunsaturated fatty acids (PUFA) enhance fibrosis and have been associated with increased oxidative damage in some models of liver injury. The aim of this study was to determine the effects of dietary fat of varying PUFA content on iron-induced oxidative stress and fibrosis. METHODS: Rats were given parenteral iron and diets supplemented with coconut oil, safflower oil or menhaden oil. RESULTS: Hepatic iron overload was associated with induction of heme oxygenase-1, a sensitive indicator of oxidative stress, and with modest increases in hydroxyproline and procollagen I mRNA levels without histologically evident fibrosis, all of which were unaffected by dietary fat. In addition, iron loading was associated with increases in cysteine, gamma-glutamylcysteine and glutathione. Dietary fat brought about the expected alterations in peroxidizability, but did not alter indices of oxidative damage. CONCLUSION: These data highlight the distinction between oxidative stress and oxidative damage and suggest that the former is not sufficient to elicit overt fibrosis. Furthermore, while hepatic iron overload leads to oxidative stress, there is an associated upregulation of antioxidant defenses involving thiol metabolism that may be a critical factor limiting the accumulation of oxidative damage.


Assuntos
Gorduras Insaturadas na Dieta/administração & dosagem , Sobrecarga de Ferro/metabolismo , Ferro da Dieta/toxicidade , Cirrose Hepática Experimental/metabolismo , Estresse Oxidativo , Animais , Colágeno Tipo I/biossíntese , Colágeno Tipo I/genética , Cisteína/metabolismo , Dipeptídeos/metabolismo , Glutationa/metabolismo , Heme Oxigenase (Desciclizante)/biossíntese , Heme Oxigenase (Desciclizante)/genética , Heme Oxigenase-1 , Hidroxiprolina/biossíntese , Hidroxiprolina/genética , Técnicas Imunoenzimáticas , Fígado/efeitos dos fármacos , Fígado/enzimologia , Fígado/patologia , Cirrose Hepática Experimental/dietoterapia , Cirrose Hepática Experimental/patologia , Masculino , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley
6.
Semin Neonatol ; 7(2): 111-9, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12208095

RESUMO

In the neonate, hyperbilirubinaemia is usually due to a combination of an increased bilirubin load and decreased bilirubin elimination. Despite an understanding of the enzymatic pathways leading to bilirubin production and elimination, very few pharmacological interventions to prevent hyperbilirubinaemia are utilized and the mainstay of treatment remains phototherapy. Previously studied pharmacological agents such as D-penicillamine, phenobarbital and clofibrate may yet prove useful. Recent clinical trials using metalloporphyrins to inhibit heme catabolism and bilirubin production provides a novel pharmacological intervention for the treatment of neonatal jaundice. The safety and efficacy of these therapies will need to be confirmed prior to widespread use.


Assuntos
Icterícia Neonatal/tratamento farmacológico , Oxirredutases atuantes sobre Doadores de Grupo CH-CH , Ágar/farmacologia , Ágar/uso terapêutico , Bilirrubina/metabolismo , Carvão Vegetal/farmacologia , Carvão Vegetal/uso terapêutico , Clofibrato/química , Clofibrato/farmacologia , Clofibrato/uso terapêutico , Medicamentos de Ervas Chinesas/farmacologia , Medicamentos de Ervas Chinesas/uso terapêutico , Heme/metabolismo , Humanos , Recém-Nascido , Icterícia Neonatal/metabolismo , Circulação Hepática/efeitos dos fármacos , Metaloporfirinas/química , Metaloporfirinas/farmacologia , Metaloporfirinas/uso terapêutico , Oxirredutases/antagonistas & inibidores , Oxirredutases/farmacologia , Oxirredutases/uso terapêutico , Penicilamina/química , Penicilamina/farmacologia , Penicilamina/uso terapêutico , Fenobarbital/química , Fenobarbital/farmacologia , Fenobarbital/uso terapêutico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA